255 related articles for article (PubMed ID: 29222829)
21. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
Vallet H; Gaillet A; Weiss N; Vanhaecke C; Saheb S; Touitou V; Franck N; Kramkimel N; Borden A; Touat M; Ricard D; Verny M; Maisonobe T; Psimaras D
Ann Oncol; 2016 Jul; 27(7):1352-3. PubMed ID: 26940685
[No Abstract] [Full Text] [Related]
22. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
23. Pembrolizumab-associated inflammatory myopathy.
Gandiga PC; Wang AR; Gonzalez-Rivera T; Sreih AG
Rheumatology (Oxford); 2018 Feb; 57(2):397-398. PubMed ID: 29088490
[No Abstract] [Full Text] [Related]
24. Linear bullous lichen planus associated with nivolumab.
Biolo G; Caroppo F; Salmaso R; Alaibac M
Clin Exp Dermatol; 2019 Jan; 44(1):67-68. PubMed ID: 29920744
[No Abstract] [Full Text] [Related]
25. Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma.
Uthayakumar AK; Rudd E; Noy M; Weir J; Larkin J; Fearfield L
Australas J Dermatol; 2021 Aug; 62(3):403-406. PubMed ID: 34216144
[TBL] [Abstract][Full Text] [Related]
26. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
27. Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation.
Komori T; Honda T; Irie H; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e382-e384. PubMed ID: 28295693
[No Abstract] [Full Text] [Related]
28. PD-1 Blockade-induced Inflammatory Arthritis.
Nobashi T; Mittra E
Radiology; 2018 Dec; 289(3):616. PubMed ID: 30277446
[No Abstract] [Full Text] [Related]
29. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
30. New Yellow Plaques in a Patient Taking Pembrolizumab.
Massey PR; Jones KM; Fox MC
JAMA Oncol; 2017 Jan; 3(1):119-120. PubMed ID: 27892986
[No Abstract] [Full Text] [Related]
31. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
32. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
33. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
34. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
[No Abstract] [Full Text] [Related]
35. Generalised morphea induced by pembrolizumab.
Herrscher H; Tomasic G; Castro Gordon A
Eur J Cancer; 2019 Jul; 116():178-181. PubMed ID: 31202088
[No Abstract] [Full Text] [Related]
36. Vulvar lichen planus is best treated with high-potency creams.
Harv Womens Health Watch; 2006 Jun; 13(10):4-5. PubMed ID: 16841382
[No Abstract] [Full Text] [Related]
37. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab-induced lobular panniculitis in the setting of metastatic melanoma.
Peterman CM; Robinson-Bostom L; Paek SY
Cutis; 2020 Jan; 105(1):E22-E23. PubMed ID: 32074162
[No Abstract] [Full Text] [Related]
39. Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
Kida A; Matsuda K; Matsuda M; Sakai A
J Gastroenterol Hepatol; 2019 Sep; 34(9):1478. PubMed ID: 31197882
[No Abstract] [Full Text] [Related]
40. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
